Key Highlights

  • 8.1 is the second quarter 2026 Revenue in USD million reported by Rapid Micro Biosystems (NASDAQ:RPID), up 10.9% from USD 7.3 million, with Recurring Revenue of USD 5.0 million representing 63% of the total.
  • 15.0% is the gross Margin the company posted in the second quarter of 2026, compared with 3.8% in the same quarter of 2025, and management describes the result as a positive inflection.
  • 37.0 to 41.0 is the full-year 2026 revenue guidance range in USD million, alongside a target of 30 to 38 Growth Direct placements and at least 27 system validations.
  • 20.1 is the total cash, investments and restricted cash in USD million at June 30, 2026, down from USD 38.6 million at December 31, 2025, against notes payable of USD 19.1 million.

What Investors Expect From Rapid Micro Biosystems (NASDAQ:RPID) on November 16, 2026

Rapid Micro Biosystems is scheduled to report third quarter 2026 results on November 16, 2026. The prior-year benchmark is the second quarter, when revenue was USD 8.1 million, product revenue was USD 5.3 million and service revenue was USD 2.8 million. Net loss was USD 12.9 million, or 0.27 per share, compared with USD 11.9 million, or 0.27 per share, a year earlier. Full-year guidance of USD 37.0 million to USD 41.0 million, less first-half revenue of USD 16.1 million, implies second-half revenue of USD 20.9 million to USD 24.9 million (calculated).

The Rationale: Last Reported Quarter and Management Outlook for Rapid Micro Biosystems (NASDAQ:RPID)

Second quarter gross margin was USD 1.2 million, or 15.0%, versus 3.8% a year earlier, while operating expenses rose 8.9% to USD 13.5 million. Adjusted EBITDA loss was USD 10.3 million versus USD 10.1 million. The company placed 4 Growth Direct systems and completed 9 validations versus 2. Management guides to total gross margin of about 20% for 2026, with the second half in the mid-20% range, and raised its validation target to at least 27 from at least 25. The CEO cited customer engagement, multi-system deployments and growth in the MilliporeSigma collaboration as drivers, while consumable revenue rose more than 20%.

Valuation, Liquidity and Risks for Rapid Micro Biosystems (NASDAQ:RPID)

At June 30, 2026 the company held USD 14.7 million of cash and USD 5.1 million of short-term investments. Operating Activities used USD 27.76 million in the first half. A May 2026 offering raised about USD 8.8 million net. The Trinity Capital Loan agreement provides up to USD 45.0 million, of which USD 20.0 million has been drawn, and a further Tranche is expected in January 2027 if revenue and gross margin milestones are met. Shares outstanding as of July 31, 2026 were 45,660,027 Class A and 4,499,529 Class B. Risks include continued losses, dilution, possible delisting and dependence on the Growth Direct platform.

Where Things Stand

Rapid Micro Biosystems (NASDAQ:RPID) reports on November 16, 2026 with 2026 guidance of USD 37.0 million to USD 41.0 million in revenue, 30 to 38 placements and a gross margin near 20%. First-half revenue of USD 16.1 million and a first-half net loss of USD 27.2 million frame the second-half task, which requires USD 20.9 million to USD 24.9 million of revenue (calculated). Recurring revenue of 63% of the total and a margin that improved from 3.8% to 15.0% support the case for scale benefits. Liquidity of USD 20.1 million and the staged Trinity loan remain the key Balance Sheet considerations.